[ Herbal Remedies ]

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Familial hypercholesterolaemia (FH) is a frequent genetic disease associated with elevated and precocious risk of cardiovascular disease (CVD). Patients were categorized into three groups: (1) individuals who claim not to have diabetes and had no family history of diabetes; (2) individuals who claim not to have diabetes but had family history of diabetes; (3) individuals with diabetes. Since offspring of patients with type 2 diabetes mellitus (T2DM) are susceptible to developing insulin resistance, they are ideal for studying the early development of insulin resistance. Gene expression analysis in prediabetic subjects suggested a switch from carbohydrate toward lipid as an energy source. In other rats the activities of five enzymes involved in the synthesis and esterification of arachidonic acid were measured in renal cortex and in isolated glomeruli. The program focuses on parents as role models and provides them with hands-on tools to make small, specific behavior changes to prevent obesity and help maintain a healthy weight. The acute insulin response to glucose was not predictive of the development of diabetes when considered independently or when assessed as a function of S(I), i.e., the glucose disposition index.

However, the ethnic differences persisted after adjusting for major sociodemographic risk factors (unadjusted OR for Pashtun vs. Fasting glucose declined similarly between groups with training (-0.23 ± 0.08 vs. Conclusions: Although post-operative weight can be influenced by other factors, eg. We have found the information from CT calcium scoring very useful in identifying those patients with significant atherosclerosis who would need more intensive treatment. Based on the IAS proposed criteria, severe FH is diagnosed if LDL cholesterol levels exceed 400 mg/dL. The Family Nutrition Programs (FNP) focuses on improving the food, nutrition, and physical activity behaviors of limited-resource families, youth, and adults. High-risk features include a family history of early cardiovascular disease in first-degree relatives, hypertension, and diabetes, among others.

If you are the first person in a family to be suspected of having FH you are called the ‘index case’. In patients with advanced subclinical atherosclerosis, detected with a coronary artery calcium test or CT angiography, the ideal LDL cholesterol target is less than 70 mg/dL (although a 50% reduction is considered more realistic). Similar treatment goals are outlined for severe FH patients with clinical cardiovascular disease. All subjects attended the study unit between 0800 and 1000 h after an overnight fast. Bile-acid sequestrants or niacin would also be options for physicians looking to add a third agent. And finally, if the patient with severe FH is still unable to reduce LDL cholesterol levels by more than 50% (or to reach the less than 70 or 100 mg/dL goals), physicians can consider adding lomitapide (Juxtapid, Aegerion Pharmaceuticals) or mipomersen (Kynamro, Genzyme/Isis Pharmaceuticals), two agents approved by the US Food and Drug Administration for homozygous FH. The IAS panel acknowledges the financial cost of these medications, however, noting that the PCSK9 monoclonal antibodies are approximately $14,000 per year while mipomersen costs $176,000 annually and lomitapide can range between $235,000 to $295,000 per year.

Despite higher insulin levels, the insulin-resistant group had similar fasting free fatty acid concentrations when compared to control subjects, and systemic fatty acid production and appearance were lower. Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Children with FH are no more likely to be overweight than other kids. Santos reports receiving personal fees from Amgen, Aegerion, AstraZeneca, Akcea, Biolab, Boehringer-Ingelheim, Cerenis, Eli-Lilly, Genzyme, Kowa, Merck, Pfizer, Sanofi/Regeneron, Torrent, and Unilever. In MHS, FH documentation is not a mandatory computer field, and the information is often written as free text rather than coded, so it is unidentified by computer algorithms.

Tags: , ,